X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
JUVÉDERM® VOLBELLA® XC was first FDA–approved in 2016 for use in the lips and perioral rhytids.2 As the category leader, the JUVÉDERM® Collection of Fillers offers the broadest portfolio, and this latest approval marks the sixth approved indication in the U.S.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Juvéderm Volbella XC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Iran Expo
Not Confirmed
Contact Supplier
Details:
The net proceeds will be used for the commercialisation of ZTlido® (lidocaine topical system), a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rodman & Renshaw LLC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 05, 2024
Details:
The net proceeds will be used for the commercialisation of ZTlido® (lidocaine topical system), a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rodman & Renshaw LLC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, is being investigated in subjects with moderate to severe acute lower back pain (LBP).
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: SP-103
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Product Name: Alenura
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vaneltix Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
CITI-002 (lidocaine-halobetasol propionate) is a proprietary topical formulation intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding.
Lead Product(s): Lidocaine,Halobetasol
Therapeutic Area: Gastroenterology Product Name: CITI-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Princess Volume Plus
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
The agreement aims for the distribution of Ztlido (lidocaine), a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia, in Kingdom of Saudi Arabia.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Farouk, Maamoun Tamer & Co.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 31, 2023
Details:
SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, is being investigated in subjects with moderate to severe acute lower back pain (LBP).
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: SP-103
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
CITI-002 (lidocaine-halobetasol propionate) is a proprietary topical formulation intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding.
Lead Product(s): Lidocaine,Halobetasol
Therapeutic Area: Gastroenterology Product Name: CITI-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain management products, ZTlido (lidocaine), Gloperba (colchicine) and Elyxyb (celecoxib), for the treatment of acute and chronic pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: YA II PN
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2023
Details:
SP-103 has three times the drug load of ZTlido® (Lidocaine - 108 mg versus 36 mg) in the same adhesive system to potentially deliver a three-fold level of the drug within a targeted area, but retaining the convenience of a single topical system.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: SP-103
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: ZTlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CH Trading Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 17, 2022
Details:
ZTlido® (lidocaine topical system) 1.8%, a best-in-class prescription lidocaine topical product used for relief of pain from damaged nerves (neuropathic pain) that follows healing of shingles.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: ZTlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine that is intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder.
Lead Product(s): Halobetasol,Lidocaine
Therapeutic Area: Gastroenterology Product Name: Halo-Lido
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Product Name: Alenura
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals
Deal Size: $6.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 17, 2021
Details:
The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the application of Pliaglis.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Egis Pharmaceuticals PLC
Deal Size: Undisclosed Upfront Cash: $0.7 million
Deal Type: Licensing Agreement December 13, 2021
Details:
Scilex is dedicated to the development and commercialization of non-opioid pain management products for treatment of acute and chronic pain. Scilex’s product ZTLIDO ® (lidocaine topical system) 1.8%, a non-opioid prescription lidocaine topical product approved by the U.S. FDA.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vickers Vantage Corp I
Deal Size: $1,640.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 06, 2021
Details:
Under the terms of the Agreement, STADA will be responsible for commercializing Pliaglis in the Territories utilizing its experienced sales force.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2021
Details:
The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.
Lead Product(s): Oxybutynin,Lidocaine
Therapeutic Area: Urology Product Name: TRG-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other milestone payments.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Croma-Pharma
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 28, 2021
Details:
ZTlido® is the only lidocaine topical system that has been studied under the water stress conditions, and now has FDA label reflecting its use while showering, swimming and bathing.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: ZTlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 2016 by the FDA for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in patients over age 21.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Restylane Defyne
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.
Lead Product(s): Lidocaine,Prilocaine
Therapeutic Area: Psychiatry/Psychology Product Name: Senstend
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 02, 2020
Details:
Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Juyou Biotechnology
Deal Size: $2.9 million Upfront Cash: $0.1 million
Deal Type: Licensing Agreement November 05, 2020
Details:
Company’s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA® Collection of dermal fillers, resilient hyaluronic acid, and the HintMD financial technology (fintech) platform, in the United States (U.S.) in September.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: RHA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: $3.9 million
Deal Type: Licensing Agreement July 28, 2020
Details:
The partnership with FILLMED will allow Crescita to expand its product offering in the medical aesthetic field with the addition of the hyaluronic acid ART-Filler® injectables range and NCTF® 135 HA.
Lead Product(s): Lidocaine,Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Crescita Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 20, 2020
Details:
Under the agreement Revance will gain immediate and exclusive rights to commercialize TEOXANE’s RHA® line of fillers in the U.S.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Revance Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
